SRTS icon

Sensus Healthcare

4.69 USD
+0.05
1.08%
At close Mar 27, 4:00 PM EDT
1 day
1.08%
5 days
0.21%
1 month
-1.05%
3 months
-34.95%
6 months
-20.24%
Year to date
-33.94%
1 year
19.64%
5 years
99.57%
10 years
-19.83%
0
Funds holding %
of 7,390 funds
Analysts bullish %

Fund manager confidence

Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)

1,600% more first-time investments, than exits

New positions opened: 17 | Existing positions closed: 1

1,068% more call options, than puts

Call options by funds: $222K | Put options by funds: $19K

170% more repeat investments, than reductions

Existing positions increased: 27 | Existing positions reduced: 10

50% more capital invested

Capital invested by funds: $22.6M [Q3] → $33.9M (+$11.3M) [Q4]

30% more funds holding

Funds holding: 50 [Q3] → 65 (+15) [Q4]

6.21% more ownership

Funds ownership: 23.71% [Q3] → 29.92% (+6.21%) [Q4]

Research analyst outlook

2 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target
$12
156%
upside
Avg. target
$12.50
167%
upside
High target
$13
177%
upside

2 analyst ratings

positive
100%
neutral
0%
negative
0%
Lake Street
Ben Haynor
44% 1-year accuracy
4 / 9 met price target
177%upside
$13
Buy
Maintained
11 Mar 2025
HC Wainwright & Co.
Yi Chen
46% 1-year accuracy
74 / 162 met price target
156%upside
$12
Buy
Maintained
10 Feb 2025

Financial journalist opinion

Based on 6 articles about SRTS published over the past 30 days

Neutral
Zacks Investment Research
6 hours ago
Sensus Healthcare, Inc. (SRTS) Rises As Market Takes a Dip: Key Facts
Sensus Healthcare, Inc. (SRTS) closed the most recent trading day at $4.69, moving +1.08% from the previous trading session.
Sensus Healthcare, Inc. (SRTS) Rises As Market Takes a Dip: Key Facts
Positive
Zacks Investment Research
1 week ago
Here's Why Sensus Healthcare, Inc. (SRTS) Gained But Lagged the Market Today
Sensus Healthcare, Inc. (SRTS) closed the most recent trading day at $4.78, moving +0.84% from the previous trading session.
Here's Why Sensus Healthcare, Inc. (SRTS) Gained But Lagged the Market Today
Neutral
Business Wire
2 weeks ago
Sensus Healthcare to Participate in the 37th Annual ROTH Conference
BOCA RATON, Fla.--(BUSINESS WIRE)--Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological skin conditions, announces it will be participating in Roth Capital's 37th Annual ROTH Conference, being held March 17-18 in Dana Point, California. Management will be holding one-on-one meetings with registered investors during the conference. Registered attendees.
Sensus Healthcare to Participate in the 37th Annual ROTH Conference
Neutral
Zacks Investment Research
2 weeks ago
Brokers Suggest Investing in Sensus Healthcare (SRTS): Read This Before Placing a Bet
When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?
Brokers Suggest Investing in Sensus Healthcare (SRTS): Read This Before Placing a Bet
Neutral
Business Wire
3 weeks ago
Sensus Healthcare to Showcase Commercial and Late-Stage Products at the American Academy of Dermatology Annual Meeting
BOCA RATON, Fla.--(BUSINESS WIRE)---- $SRTS--Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological skin conditions, announces it will be showcasing its full line of commercial Superficial Radiotherapy (SRT) products including the SRT-100®, SRT-100+ and SRT-100 Vision™ systems, along with several innovative pre-commercial products, at the 2025 American Academy of.
Sensus Healthcare to Showcase Commercial and Late-Stage Products at the American Academy of Dermatology Annual Meeting
Neutral
Business Wire
3 weeks ago
Sensus Healthcare Announces Publication of Study at Tri Service Military Hospital in Taiwan Demonstrating Efficacy of SRT-100® in Preventing Keloid Recurrence
BOCA RATON, Fla.--(BUSINESS WIRE)--Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological skin conditions, announces the publication of a study titled "Keloid Excision With Primary Closure Combined With Superficial Radiation Therapy (SRT-100)" in the Annals of Plastic Surgery. The single-site, retrospective study evaluated the clinical outcomes of combin.
Sensus Healthcare Announces Publication of Study at Tri Service Military Hospital in Taiwan Demonstrating Efficacy of SRT-100® in Preventing Keloid Recurrence
Neutral
Business Wire
1 month ago
Sensus Healthcare Buys Back Shares
BOCA RATON, Fla.--(BUSINESS WIRE)--Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological skin conditions, announces that the company has resumed purchasing shares of its common stock in open-market transactions under a $3.0 million share repurchase program approved by its Board of Directors and announced in August 2023. “We are implementing this program.
Sensus Healthcare Buys Back Shares
Neutral
Seeking Alpha
1 month ago
Sensus Healthcare: A Tough Q1 2025 Awaits Ahead
Q4 2024 showed a significant miss in profitability despite a 4% YoY sales growth; gross profit margin dropped due to a one-time discount for a new big client. The FDA initiatives are interesting, but they will bring a slowdown in sales as they are fully rolled out. Management has warned of a Q1 2025 with considerably lower sales due to the Fair Deal Agreements and seasonal factors.
Sensus Healthcare: A Tough Q1 2025 Awaits Ahead
Neutral
Seeking Alpha
1 month ago
Sensus Healthcare, Inc. (SRTS) Q4 2024 Earnings Call Transcript
Sensus Healthcare, Inc. (NASDAQ:SRTS ) Q4 2024 Earnings Conference Call February 5, 2025 4:30 PM ET Company Participants Tirth Patel - Alliance Advisors, IR Joe Sardano - Chairman and CEO Michael Sardano - President & General Counsel Javier Rampolla - CFO Conference Call Participants Jeremy Pearlman - Maxim Group Arsalan Cameron - Roth Capital Partners Ben Haynor - Lake Street Capital Markets Operator Good day, and welcome to the Sensus Healthcare Fourth Quarter 2024 Financial Results Conference Call. [Operator Instructions].
Sensus Healthcare, Inc. (SRTS) Q4 2024 Earnings Call Transcript
Negative
Zacks Investment Research
1 month ago
Sensus Healthcare, Inc. (SRTS) Lags Q4 Earnings Estimates
Sensus Healthcare, Inc. (SRTS) came out with quarterly earnings of $0.09 per share, missing the Zacks Consensus Estimate of $0.10 per share. This compares to earnings of $0.26 per share a year ago.
Sensus Healthcare, Inc. (SRTS) Lags Q4 Earnings Estimates
Charts implemented using Lightweight Charts™